Edition:
Deutschland

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

63.43USD
19:11 Uhr
Change (% chg)

$-0.20 (-0.31%)
Prev Close
$63.63
Open
$63.46
Day's High
$63.56
Day's Low
$63.07
Volume
381,373
Avg. Vol
1,558,631
52-wk High
$65.89
52-wk Low
$48.58

ABT.N

Chart for ABT.N

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Buy/Sell

▼
Sell Hold Buy
1.78 Mean rating from 18 analysts

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

Latest News about ABT.N

FACTBOX-U.S. companies with exposure to Russia

Aug 9 Although the United States and Russia have imposed economic sanctions on each other since 2014, several large U.S. corporations, including PepsiCo Inc and McDonald's Corp, still count Russia as a growth market.

UPDATE 2-Abbott Labs raises 2018 earnings forecast, shares hit record high

* Shares hit record high (Adds details from conference call, analysts' quotes, updates shares)

Abbott Labs tops profit estimates, raises full-year earnings forecast

July 18 Abbott Laboratories raised its full-year earnings forecast and reported a quarterly profit that beat analysts' estimates, powered by higher sales across its businesses, including its top-earning medical device unit.

Photo

Allergan appoints former Abbott executive to its board

Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

Allergan appoints former Abbott executive to its board

June 14 Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

UPDATE 4-Medical device maker Stryker makes takeover approach to Boston Scientific -WSJ

June 11 Medical device maker Stryker Corp has made a takeover approach to rival Boston Scientific Corp, the Wall Street Journal reported https://www.wsj.com/articles/stryker-has-made-a-takeover-approach-to-boston-scientific-1528727749?mod=searchresults&page=1&pos=1 on Monday, a combination that would give Stryker a strong position in stroke-preventing heart products.

BRIEF-Abbott Says Newest Generation Of Leading Heart Stent Now Approved In U.S. For People With Coronary Artery Disease

* ABBOTT - NEWEST GENERATION OF LEADING HEART STENT NOW APPROVED IN U.S. FOR PEOPLE WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:

BRIEF-Abbott Expands Cardiac Arrhythmias Portfolio With FDA Clearance Of Advanced Mapping Catheter

* ABBOTT EXPANDS CARDIAC ARRHYTHMIAS PORTFOLIO WITH FDA CLEARANCE OF ADVANCED MAPPING CATHETER

BRIEF-Abbott's Xience Sierra Heart Stent Receives National Reimbursement In Japan

* ABBOTT'S XIENCE SIERRA™ HEART STENT RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PEOPLE WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:

» More ABT.N News

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -2.09%
Rohstoffe -0.75%
Industrie -1.13%
Konjunktur abhängige Waren & Dienstleistungen -0.28%
Konjunktur unabhängige Waren & Dienstleistungen -0.44%
Finanzindustrie -0.44%
Pharma -1.27%
Technologie -0.07%
Telekommunikation +0.33%

Nachrichten aus der Wirtschaft

Photo

US-Einzelhandel mit gutem Start ins zweite Halbjahr

Washington Die US-Einzelhändler sind mit überraschend viel Rückenwind in die zweite Jahreshälfte gestartet.